| Literature DB >> 26944724 |
Mei-Fang Li1,2, Cui-Chun Zhao3, Ting-Ting Li4, Yin-Fang Tu5, Jun-Xi Lu6, Rong Zhang7, Ming-Yun Chen8, Yu-Qian Bao9, Lian-Xi Li10, Wei-Ping Jia11.
Abstract
BACKGROUND: Both carotid and lower limb atherosclerosis are associated with increased cardiovascular and cerebrovascular risks. However, it is still unclear whether the concomitant presence of carotid and lower extremity atherosclerosis further increases the cardiovascular and cerebrovascular risks. Therefore, our aim is to investigate whether the coexistence of carotid and lower extremity atherosclerosis was associated with higher cardiovascular and cerebrovascular risks in patients with type 2 diabetes.Entities:
Mesh:
Year: 2016 PMID: 26944724 PMCID: PMC4779218 DOI: 10.1186/s12933-016-0360-2
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Characteristics of the study subjects
| Variables | Without AS (n = 711) | With either carotid or lower limb AS (n = 999) | With both carotid and lower limb AS (n = 1120) | p value | *p value |
|---|---|---|---|---|---|
| Age (months) | 49 ± 11 | 60 ± 10 | 67 ± 10 | <0.001 | <0.001 |
| Male (n, %) | 325 (45.7 %) | 446 (44.6 %) | 475 (42.4 %) | 0.340 | <0.001 |
| DD (months)a | 48 (3–96) | 84 (24–132) | 120 (48–168) | <0.001 | <0.001 |
| Smoking (n, %) | 226 (31.79 %) | 291 (29.13 %) | 281 (25.09 %) | 0.007 | 0.612 |
| Alcohol (n, %) | 115 (16.17 %) | 171 (17.12 %) | 142 (12.68 %) | 0.014 | 0.036 |
| Hypertension (n, %) | 256 (36.00 %) | 521 (52.20 %) | 742 (66.20 %) | <0.001 | <0.001 |
| Dyslipidemia (n, %) | 546 (76.8 %) | 729 (73.0 %) | 857 (76.5 %) | 0.041 | 0.001 |
| IIAs (n, %) | 486 (68.4 %) | 687 (68.8 %) | 849 (75.8 %) | <0.001 | <0.001 |
| LLD (n, %) | 189 (26.6 %) | 292 (29.2 %) | 402 (35.9 %) | <0.001 | <0.001 |
| AHAs (n, %) | 224 (31.5 %) | 479 (47.9 %) | 692 (61.8 %) | <0.001 | <0.001 |
| APAs (n, %) | 96 (13.5 %) | 534 (53.5 %) | 827 (73.8 %) | <0.001 | <0.001 |
| BMI (kg/m2) | 24.97 ± 3.48 | 24.92 ± 3.41 | 24.78 ± 3.43 | 0.476 | 0.888 |
| WHR (cm) | 0.91 ± 0.06 | 0.91 ± 0.06 | 0.92 ± 0.07 | 0.004 | 0.206 |
| SBP (mmHg) | 126 ± 15 | 132 ± 17 | 136 ± 18 | <0.001 | <0.001 |
| DBP (mmHg) | 80 ± 10 | 80 ± 10 | 80 ± 10 | 0.448 | 0.006 |
| TC (mmol/l) | 4.72 ± 1.14 | 4.72 ± 1.13 | 4.74 ± 1.15 | 0.943 | <0.001 |
| TTG (mmol/l)a | 1.57 (1–2.48) | 1.39 (0.97–2.12) | 1.39 (1–1.96) | <0.001 | 0.456 |
| HDL-C (mmol/l) | 1.09 ± 0.32 | 1.13 ± 0.3 | 1.12 ± 0.3 | 0.018 | 0.120 |
| LDL-C (mmol/l) | 3.07 ± 0.94 | 3.09 ± 0.9 | 3.15 ± 1.01 | 0.148 | <0.001 |
| HbA1C (%) | 9.22 ± 2.36 | 9.05 ± 2.36 | 9.12 ± 2.46 | 0.346 | 0.290 |
| FPG (mmol/l)a | 8.05 (6.56–10.09) | 7.61 (6.17–9.67) | 7.55 (6.01–9.39) | <0.001 | 0.572 |
| 2h PPG (mmol/l)a | 13.76 (10.32–17.18) | 13.23 (9.94–16.49) | 13.66 (10.22–16.98) | 0.246 | 0.519 |
| FCPa | 1.69 (1.03–2.48) | 1.68 (1.07–2.44) | 1.61 (0.92–2.43) | 0.223 | 0.234 |
| 2h PCPa | 3.72 (2.17–5.39) | 3.81 (2.22–5.47) | 3.49 (1.92–5.26) | 0.034 | 0.002 |
| ALT (U/L)a | 21 (15–35) | 20 (14–31) | 17 (12–26) | <0.001 | 0.225 |
| Cr (mmol/l)a | 62 (51–73) | 67 (56–79) | 71 (58–87) | <0.001 | 0.003 |
| UAE (mg/24 h)a | 9.8 (6.2–20.1) | 11.06 (6.3–25.88) | 12.4 (7.1–50) | <0.001 | 0.005 |
| eGFR (ml/min/1.73 m2) m2) | 113 (98–132) | 99 (84–118) | 92 (74–111) | <0.001 | 0.370 |
| SUA (μmol/l)a | 308 (252–366) | 305 (254–367) | 317 (260–383) | 0.003 | 0.034 |
| CRPa | 0.99 (0.43–2.26) | 1.07 (0.46–2.52) | 1.36 (0.6–3.8) | <0.001 | 0.198 |
Values are presented as mean ± SD, median with interquartile range, or percentages
aNon-normal distribution of continuous variables
p value: The p values were not adjusted for age and sex for the trend
* p value: The * p value were adjusted by sex and age for the trend
Fig. 1Characteristics of CCBVEs of the entire subjects a The prevalence of CCBVEs stratified by sex after adjusting on age and DD. The p value for sex comparison was 0.400. b The prevalence of CCBVEs stratified by age after adjusting on sex and DD. The p value for group comparison was <0.001. c The distribution of CCBVEs after adjusting on sex, age and DD. The prevalence of isolated CVEs, isolated CBVEs and combined CVEs and CBVEs was successively 2.1, 12.5 and 0.9 %. The p value for group comparison was <0.001. d The prevalence of CCBVEs stratified by duration of diabetes after adjusting on sex and age. The p value for group comparison was <0.001
Fig. 2Characteristics of self-reported CCBVDs of the whole subjects a The prevalence of CCBVDs stratified by sex after adjusting on age and DD. The p value for sex comparison was 0.474. b The prevalence of CCBVDs stratified by age after adjusting on sex and DD. The p value for group comparison was <0.001. c The distribution of CCBVDs after adjusting on sex, age and DD. The prevalence of isolated CVDs, isolated CBVDs and both CVDs and CBVDs was successively 8.4, 11.8 and 3.1 %. The p value for group comparison was <0.001. d The prevalence of CCBVDs stratified by duration of diabetes after adjusting on sex and age. The p value for group comparison was <0.001
Fig. 3Comparison of IMT in carotid and femoral among the three groups a Comparison of CIMT among the three groups after adjustment on age, sex and DD. The p value for group comparison was <0.001. b Comparison of FIMT among the three groups after adjustment on age, sex and DD. The p value for group comparison was <0.001
Fig. 4Comparison of the prevalence of CCBVEs and self-reported CCBVDs among the three groups a Comparison of the prevalence of CVEs among the three groups after adjustment on age, sex and DD. The p value for group comparison was <0.001. b Comparison of the prevalence of CBVEs among the three groups after adjustment on age, sex and DD. The p value for group comparison was <0.001. c Comparison of the prevalence of CCBVEs among the three groups after adjustment on age and sex. The p value for group comparison was <0.001. d Comparison of the prevalence of CVDs among the three groups after adjustment on age, sex and DD. The p value for group comparison was <0.001. e Comparison of the prevalence of CBVDs among the three groups after adjustment on age, sex and DD. The p value for group comparison was <0.001. f Comparison of the prevalence of CCBVDs among the three groups after adjustment on age, sex and DD. The p value for group comparison was <0.001
Associations between carotid, lower-limb atherosclerosis and CVEs, CBVEs, CCBVEs
| ORs (95 % CI) | p value for trend | |||
|---|---|---|---|---|
| Without AS | With either carotid or lower limb AS | With both carotid and lower limb AS | ||
| CVEs | ||||
| Model I | 1 (ref) | 6.405 (1.484–27.651) | 13.841 (3.322–57.677) | <0.001 |
| Model II | 1 (ref) | 6.090 (1.405–26.399) | 13.302 (3.183–55.589) | <0.001 |
| Model III | 1 (ref) | 4.742 (1.050–21.411) | 11.306 (2.602–49.129) | <0.001 |
| CBVEs | ||||
| Model I | 1 (ref) | 1.429 (0.869–2.350) | 2.218 (1.351–3.642) | 0.001 |
| Model II | 1 (ref) | 1.401 (0.833–2.356) | 2.169 (1.290–3.645) | 0.002 |
| Model III | 1 (ref) | 1.389 (0.780–2.475) | 2.092 (1.1710–3.738) | 0.011 |
| CCBVEs | ||||
| Model I | 1 (ref) | 1.690 (1.052–2.714) | 2.708 (1.681–4.362) | <0.001 |
| Model II | 1 (ref) | 1.685 (1.030–2.756) | 2.749 (1.675–4.510) | <0.001 |
| Model III | 1 (ref) | 1.724 (1.001–2.966) | 2.869 (1.660–4.960) | <0.001 |
Model I: Adjusted for age, sex, smoking, alcohol, DD, MetS, hypertension and CKD
Model II: Adjusted for age, sex, smoking, alcohol, DD, MetS, hypertension, CKD, BMI, WHR, SBP and DBP
Model III: Adjusted for age, sex, smoking, alcohol, DD, MetS, hypertension, CKD, BMI, WHR, SBP, DBP, FPG, 2h PPG, HbA1c, CRP, FCP, 2h C-P, SCr, SUA, TG, TC, HDL-C and LDL-C
Associations between carotid, lower-limb atherosclerosis and self-reported CVDs, CBVDs, CCBVDs
| ORs (95 % CI) | p value for trend | |||
|---|---|---|---|---|
| Without AS | With either carotid or lower limb AS | With both carotid and lower limb AS | ||
| CVDs | ||||
| Model I | 1 (ref) | 1.839 (1.118–3.025) | 2.305 (1.387–3.832) | 0.005 |
| Model II | 1 (ref) | 2.002 (1.189–3.371) | 2.543 (1.492–4.333) | 0.002 |
| Model III | 1 (ref) | 1.899 (1.057–3.413) | 2.667 (1.467–4.847) | 0.003 |
| CBVDs | ||||
| Model I | 1 (ref) | 1.515 (0.949–2.418) | 2.123 (1.327–3.397) | 0.002 |
| Model II | 1 (ref) | 1.472 (0.905–2.396) | 2.077 (1.272–3.389) | 0.004 |
| Model III | 1 (ref) | 1.582 (0.920–2.721) | 2.114 (1.220–3.661) | 0.017 |
| CCBVDs | ||||
| Model I | 1 (ref) | 1.587 (1.103–2.283) | 2.023 (1.394–2.936) | 0.001 |
| Model II | 1 (ref) | 1.597 (1.093–2.333) | 2.029 (1.376–2.993) | 0.001 |
| Model III | 1 (ref) | 1.705 (1.115–2.605) | 2.147 (1.388–3.320) | 0.002 |
Model I: Adjusted for age, sex, smoking, alcohol, DD, MetS, hypertension and CKD
Model II: Adjusted for age, sex, smoking, alcohol, DD, MetS, hypertension, CKD, BMI, WHR, SBP and DBP
Model III: Adjusted for age, sex, smoking, alcohol, DD, MetS, hypertension, CKD, BMI, WHR, SBP, DBP, FPG, 2h PPG, HbA1c, CRP, FCP, 2h C-P, SCr, SUA, TG, TC, HDL-C and LDL-C